Live Free or Die Legal
This website is not an official source of law. This website does not provide legal advice. For official legal materials, verify against the relevant court, legislature, agency, or other official source. Legal information may be incomplete, outdated, or incorrectly processed. Consult a qualified attorney for advice about a specific legal matter.

This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 318:51-a · Licensing of Manufacturers and Wholesalers Required

Title
XXX: OCCUPATIONS AND PROFESSIONS
Chapter
318 · PHARMACISTS AND PHARMACIES
Status
current
Official source linked
Yes
Official source Copy section link

318:51-a Licensing of Manufacturers and Wholesalers Required. –

Copy link
I.

No person shall manufacture legend drugs or controlled drugs as that term is defined in RSA 318-B:1, VI and no person as a wholesaler, distributor, or reverse distributor shall supply the same without first having obtained a license to do so from the office of professional licensure and certification according to the eligibility requirements set forth in rule by the pharmacy board.

Copy link
II.

No license shall be issued under this section unless the applicant has furnished proof:

Copy link
(a)

That the applicant is of good moral character or, if that applicant is an association or corporation, that the managing officers are of good moral character.

Copy link
(b)

That the applicant has sufficient land, buildings, and such security equipment so as to properly carry on the business described in his application.

Copy link
III.

No license shall be granted to any person who has within 5 years been convicted of a violation of any law of the United States, or of any state, relating to drugs, as defined in this chapter or RSA 318-B, or to any person who is a drug-dependent person.

Copy link
IV.

Any person licensed pursuant to this section is subject to the provisions of RSA 318:29.

Copy link
V.

(a) The manufacturer, wholesaler, distributor, reverse distributor, or broker to which a license has been issued shall, within 30 days of any change of information supplied in the original application, notify the office.

Copy link
(b)

The notice required pursuant to subparagraph (a) shall contain:

Copy link
(1)

Current New Hampshire license number of the manufacturer, wholesaler, distributor, reverse distributor, or broker.

Copy link
(2)

Name of the manufacturer, wholesaler, distributor, reverse distributor, or broker, old and new, if applicable.

Copy link
(3)

Address of the manufacturer, wholesaler, distributor, reverse distributor, or broker, old and new, if applicable.

Copy link
(4)

[Repealed.]

Copy link
(c)

A new license shall be required for a change of ownership of an established manufacturer, wholesaler, distributor, reverse distributor, or broker to a successor business entity which results in a change in the controlling interest in the manufacturer, wholesaler, distributor, reverse distributor, or broker. Source. 1985, 324:15. 1989, 258:3. 2011, 111:2, 3, eff. July 30, 2011. 2019, 264:10, 15, IV, eff. Sept. 17, 2019. 2024, 327:134, eff. July 1, 2024.

Copy link

Source note

Source. 1985, 324:15. 1989, 258:3. 2011, 111:2, 3, eff. July 30, 2011. 2019, 264:10, 15, IV, eff. Sept. 17, 2019. 2024, 327:134, eff. July 1, 2024.

Source history

  • 1985, 324:15
  • 1989, 258:3
  • 2011, 111:2, 3, eff. July 30, 2011
  • 2019, 264:10, 15, IV, eff. Sept. 17, 2019
  • 2024, 327:134, eff. July 1, 2024

Related materials

Bill relationships

  • 2026 HB1249 reference

    rvices and Elderly Affairs ----------------------------------------------------------------- ANALYSIS This bill amends the definition of the practice of pharmacy under RSA 318 and authorizes pharmacists to prescribe certain prescription devices necessary for the appropriate delivery or administration of a prescribed drug. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

  • 2026 HB1584 amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 HB1584-FN amend · effective 2027-01-01

    each operated at a surplus for the past year. In no case shall the commissioner make such certification prior to July 1, 2027. 9 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB504 reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB504-FN reference · effective 2027-01-01

    including rules to enforce the requirements of this section. V. Nothing in this section shall be construed to alter the jurisdiction or authority of the board of pharmacy under RSA 318. 126-ZZ:7 Free Care and Public Benefits. I. Each licensed experimental treatment center shall allocate 2 percent of its net annual profits to support access to experimental treatments and health care for qualifyin

  • 2026 SB665 amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2026 SB665-FN amend · effective 2027-01-01

    s used to compensate the pharmacy benefits manager. VII. Nothing in this section shall prohibit the use of spread pricing. 13 New Subdivision; Drug Pricing Options. Amend RSA 318 by inserting after section 47-m the following new subdivision: Drug Pricing Options 318:47-n Notice of Drug Pricing Options. I. Every pharmacy licensed in this state shall make reasonable efforts to notify cons

  • 2025 HB254 reference

    ician licensed pursuant to RSA 329; (2) An osteopathic physician licensed pursuant to RSA 329; (3) An advanced practice registered nurse licensed pursuant to RSA 326-B; or (4) A pharmacist licensed pursuant to RSA 318; provided, however, that a pharmacist shall not qualify as an attending health care provider under RSA 137-M:1, II or as a consulting health care provider under RSA 137-M:1, III. (b) A "health care provider" d

  • 2025 HB63 reference

    may write a prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine for the postsecondary educational institution or independent school. IV. A pharmacist licensed under RSA 318 may dispense a valid prescription, drug order, or protocol for epinephrine nasal spray or auto-injectable epinephrine issued in the name of a postsecondary educational institution or an independent school. 200